Table 1.
Participants’ Demographic and Clinical Characteristics (N=160)
| Age, m (SD) | ||
| Years | 9.31 | (2.20) |
| Gender, n (%) | ||
| Male | 126 | (78.75) |
| Female | 34 | (21.25) |
| Race or Ethnic Group, n (%) | ||
| White | 94 | (58.75) |
| African-American | 25 | (15.63) |
| Hispanic | 31 | (19.38) |
| Other or mixed heritage | 10 | (6.25) |
| Diagnoses Comorbid with ADHD, n (%) | ||
| Oppositional defiant disorder | 143 | 89.38 |
| Conduct disorder | 17 | 10.63 |
| Anxiety disorder | 39 | 24.53 |
| Mood disorder | 18 | 11.32 |
| Optimized Stimulant Monotherapy Regimen, n (%) | ||
| Stimulant Preparation | ||
| Methylphenidate, triphasic release | 100 | 62.50 |
| Methylphenidate, biphasic release | 16 | 10.00 |
| Mixed amphetamine salts, extended release | 38 | 23.75 |
| Other | 6 | 3.75 |
| Total daily dose in MPH equivalent, m (SD) | ||
| Complete sample | 43.07 | 15.63 |
| Aggression-remitted group | 42.02 | 16.06 |
| Aggression-refractory group | 44.61 | 16.58 |
| Days from baseline assessment to final stimulant monotherapy endpoint assessment, m (SD) | ||
| Complete sample | 70.22 | 37.47 |
| Aggression-remitted group | 67.90 | 35.73 |
| Aggression-refractory group | 72.66 | 39.30 |
Note: ADHD = attention-deficit/hyperactivity disorder; MPH = methylphenidate